Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Read full article: Expect roller coaster temps plus rounds of rain for the next 7 days The Annual State of the County Address for Botetourt County is set to be held Thursday at 8 a.m. Read full ...

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as ...

Jared Holz, Mizuho, joins 'Fast Money' to talk how to play Eli Lilly's stock right now ... Jones steps down as president of MSNBC See photos of 20 iconic sitcom casts when their show started ...

A reporter uncovers evidence that research fraud on a massive scale has hyped the potential benefit of expensive drugs aimed ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

Lilly plans to share its full Q4 2024 results on 6 February 2025. Credit: JHVEPhoto via Getty Images. Eli Lilly has announced a $400m reduction in its 2024 revenue forecast, marking a 3% shortfall ...

Eli Lilly saw its shares crash in early trade on Tuesday as the ... text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...